Diagnostic role of CD64 expression on neutrophils as biomarker for blood stream infection in liver cirrhosis: some preliminary findings.

CD64 expression on neutrophils biomarkers blood stream infection liver cirrhosis mortality teamwork

Journal

Le infezioni in medicina
ISSN: 2532-8689
Titre abrégé: Infez Med
Pays: Italy
ID NLM: 9613961

Informations de publication

Date de publication:
2024
Historique:
received: 24 05 2024
accepted: 17 07 2024
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 16 9 2024
Statut: epublish

Résumé

The expression of CD64 on neutrophils (nCD64), measured using flow cytometry, has been proposed as a biomarker for bloodstream infections (BSI). However, data regarding its use in the setting of liver cirrhosis are lacking. We compared nCD64 levels in 15 cirrhotic patients with BSI to those in 19 controls, including outpatients with stable decompensated cirrhosis without infection. Additionally, we compared nCD64 with C-reactive protein (CRP) and procalcitonin (PCT) in infected hospitalized cirrhotic patients. Cirrhotic patients with infection had higher levels of nCD64 compared to controls (6.0 [5.4-7.1] vs. 2.0 [1.5-2.2]; p<0.001). Among infected patients, a correlation between nCD64 (AUC=0.934 [0.875-0.982 95% CI]), CRP (AUC=0.972 [0.942-0.993 95% CI]), and PCT (AUC=0.859 [0.739-0.953 95% CI]) was observed. However, in our sample of cirrhotic individuals, nCD64 values were not significantly different between patients with worse prognosis and those with positive outcomes (p=0.448), and its expression was not influenced by Gram stain. In our cohort, nCD64 appears to be a promising new biomarker for BSI. Additional prospective studies are needed to confirm its role and limitations in conjunction with other biomarkers and rapid microbiology in the diagnostic multidisciplinary pathway for septic cirrhotic patients.

Sections du résumé

Background UNASSIGNED
The expression of CD64 on neutrophils (nCD64), measured using flow cytometry, has been proposed as a biomarker for bloodstream infections (BSI). However, data regarding its use in the setting of liver cirrhosis are lacking.
Methods UNASSIGNED
We compared nCD64 levels in 15 cirrhotic patients with BSI to those in 19 controls, including outpatients with stable decompensated cirrhosis without infection. Additionally, we compared nCD64 with C-reactive protein (CRP) and procalcitonin (PCT) in infected hospitalized cirrhotic patients.
Results UNASSIGNED
Cirrhotic patients with infection had higher levels of nCD64 compared to controls (6.0 [5.4-7.1] vs. 2.0 [1.5-2.2]; p<0.001). Among infected patients, a correlation between nCD64 (AUC=0.934 [0.875-0.982 95% CI]), CRP (AUC=0.972 [0.942-0.993 95% CI]), and PCT (AUC=0.859 [0.739-0.953 95% CI]) was observed. However, in our sample of cirrhotic individuals, nCD64 values were not significantly different between patients with worse prognosis and those with positive outcomes (p=0.448), and its expression was not influenced by Gram stain.
Conclusions UNASSIGNED
In our cohort, nCD64 appears to be a promising new biomarker for BSI. Additional prospective studies are needed to confirm its role and limitations in conjunction with other biomarkers and rapid microbiology in the diagnostic multidisciplinary pathway for septic cirrhotic patients.

Identifiants

pubmed: 39282535
doi: 10.53854/liim-3203-10
pii: 1124-9390_32_3_2024_363-368
pmc: PMC11392555
doi:

Types de publication

Journal Article

Langues

eng

Pagination

363-368

Déclaration de conflit d'intérêts

Competing interests: No conflict of interest must be declared for any of the authors.

Auteurs

Elena Garlatti Costa (EG)

Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Sergio Venturini (S)

Department of Infectious Diseases, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Gian Luca Colussi (GL)

Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Chiara Pratesi (C)

Department of Laboratory Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Danilo Villalta (D)

Department of Immunology and Allergology, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Anna Sabena (A)

Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Alessandro Grembiale (A)

Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Elisa Pontoni (E)

Department of Emergency Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Igor Bramuzzo (I)

Department of Infectious Diseases, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Giuseppe Barbato (G)

Department of Emergency Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Massimiliano Balbi (M)

Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of San Vito al Tagliamento, Italy.

Paolo Doretto (P)

Department of Laboratory Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Manuela Avolio (M)

Department of Microbiology and Virology, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Giancarlo Basaglia (G)

Department of Microbiology and Virology, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Massimo Crapis (M)

Department of Infectious Diseases, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Maurizio Tonizzo (M)

Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Stefano Fagiuoli (S)

Gastroenterology Hepatology and Transplantation Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Hospital of Bergamo, Italy.

Silvia Grazioli (S)

Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, Hospital of Pordenone, Italy.

Classifications MeSH